Semax
A synthetic heptapeptide derived from the 4–10 fragment of adrenocorticotrophic hormone (ACTH), developed in Russia in the 1980s and registered there as a pharmaceutical for ischaemic stroke. Reportedly investigated for neuroprotective, cognitive, and anxiolytic effects; administered as a nasal spray in countries where it is approved. The primary evidence base is concentrated in Russian-language and Russian-journal literature; representation in internationally indexed journals is limited, substantially constraining independent evaluation.
Side effects & risks
Semax has been approved as a pharmaceutical in Russia and has an associated clinical safety record from that context, though the body of published trial data available in indexed international literature is limited and dominated by Russian-language sources. This regulatory history provides a different baseline than purely preclinical compounds, but should not be conflated with approval by the US FDA, EMA, or comparable agencies, each of which applies its own independent evaluation standards.
In the published clinical data from Russian trials, the most commonly reported adverse events were mild and transient: irritation at the intranasal administration site, mild headache, and transient dizziness. These events were typically reported as resolving without intervention. The intranasal route used in the approved Russian formulation is not directly comparable to injectable routes described in some community reports.
Semax's proposed mechanism — BDNF upregulation and melanocortin receptor activity — raises theoretical concerns about effects on neuroplasticity, mood regulation, and the HPA axis with sustained use. The long-term neurological consequences of exogenous peptides that modulate brain-derived neurotrophic factor have not been characterised for this compound in long-term human trials.
Melanocortin receptor subtypes (MC4R in particular) are involved in energy homeostasis, sexual function, and mood. Semax — as an ACTH(4–10) analogue whose minimal bioactive core is ACTH(4–7) — shows affinity for these receptors; the downstream endocrine and behavioural consequences of sustained MC receptor modulation in adults using community protocols are not characterised in peer-reviewed international literature.
Drug interactions have not been systematically studied in the Western regulatory context. Concomitant use with antidepressants, anxiolytics, or other neuroactive compounds warrants clinical judgment.
Note on literature quality: The majority of published Semax clinical studies were conducted in Russia, many published in Russian-language journals with limited availability in English-language indexed databases. Readers and the editorial team should verify cited PMIDs are indexed in PubMed before relying on specific study claims; some references in community circulation may be translated summaries rather than indexed peer-reviewed publications.
Semax is not approved for human therapeutic use in the United States, European Union (outside Russia), Australia, Canada, or the UK. Individuals obtaining it as a research chemical in these jurisdictions assume an undetermined risk profile.
Evidence summary
Latest studies
Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study.
This is a dentistry and orthodontics study, not a peptide study. It looked at ten teenagers with an underbite-type jaw problem (skeletal Class III) and tested a digitally planned method to move the upper jaw forward, using a special expander anchored to small implants plus plates on the lower jaw. After treatment, measurements showed the upper jaw had moved forward, with limited effect on the teeth themselves. The authors call it a promising, minimally invasive option that needs larger studies to confirm. It appears in this batch only because of a naming coincidence: the abstract mentions 'SeMax,' which here is a skull measurement (the distance from a point called Sella to the upper jaw) used in orthodontics — not the peptide Semax that this site covers. Because it has nothing to do with the peptide, it is being set aside to avoid confusing it with actual Semax research.
[Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome].
This study followed 42 people recovering from surgery for a detached retina, where the surgery itself had gone well. It tested whether adding a combination of physical therapies helped visual recovery. One group of 23 patients received, starting five days after surgery, breathing of a helium-oxygen mixture plus a nasal electrical-delivery treatment ('electrophoresis') of the peptide Semax. The other group of 19 received Semax as nasal drops instead. Over 12 months, the group getting the combined therapy had better recovery of corrected vision and of a detailed retinal-sensitivity measure by the six-month mark than the drops group. The authors conclude the combination is a promising rehabilitation approach. Both groups actually received Semax, just delivered differently and alongside other treatments, so the study does not show what Semax alone contributed. It was small and did not appear to randomly assign patients. It is a weak, early human signal about a rehabilitation protocol that happens to include Semax, not evidence about the peptide on its own.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, examines a broad class of research compounds called therapeutic peptides and asks whether they might have a role in orthopaedic medicine — including bone, tendon, muscle, and nerve recovery. Researchers reviewed the published scientific literature on several peptides, including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon. Each compound was evaluated for its proposed biological mechanism and its relevance to orthopaedic injury and recovery. The review found that these peptides appear to act on molecular pathways involved in tissue repair, inflammation resolution, and nerve signalling. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu were reported to promote blood vessel formation and tissue remodelling. Growth hormone-stimulating peptides like ipamorelin, CJC-1295, tesamorelin, and sermorelin were described as activating repair-related growth signals. Peptides such as epitalon were linked to cellular energy regulation, and neuroactive peptides like semax and selank were associated with nerve growth factor pathways. However, the authors explicitly noted that clinical trials in human orthopaedic patients are currently lacking. The mechanistic evidence reviewed comes primarily from laboratory and animal studies. No adverse event data specific to this review were reported in the...
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“Feedback on combined Selank/Semax”
A user asks for feedback on running Selank and Semax together. The thread discusses reported protocols for combining the anxiolytic and nootropic peptides, including timing and whether the two are typically alternated or stacked.
“Semax and Selank come from two completely unrelated molecules. They share the same three-amino-acid tail.”
An explainer thread noting that Semax derives from an ACTH fragment while Selank derives from tuftsin, yet both carry the same Pro-Gly-Pro C-terminal tail. The discussion concerns structural origin and how the shared tail relates to stability and reported effects.
“Anyone have experience with Semax or Selank peptides?”
A user in an anhedonia support community asks whether others have experience with Semax or Selank. The thread gathers reported protocols and subjective impressions on mood and motivation from those who have used either peptide.
“Nasal semax”
A thread about intranasal Semax use, covering reported protocols for concentration, spray timing, and expected onset. The discussion is practical rather than outcome-focused.
“Phenylpiracetem, Semax, And Selank Combo Spray”
The poster discusses a nasal spray combining phenylpiracetam, semax, and selank. The thread considers whether the combination makes sense and how users report dosing it.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Ischaemic stroke / neurology (Russian approved context) | Intranasal (0.1% nasal drops) | 50–200 mcg per nostril | 2–3× daily | As directed by prescribing clinician within Russian approved framework |
| Nootropic / cognitive (community-reported, international) | Intranasal | 100–600 mcg per session | 1–2× daily | 1–2 weeks (acute) to 4–8 weeks (extended) |
Frequently asked questions
- Is Semax an approved drug?
- Semax is registered as a pharmaceutical in Russia, where it has approved indications including ischaemic stroke management and certain optic nerve conditions. It is not approved by the US FDA, the European Medicines Agency, or equivalent agencies in Australia, Canada, or the UK. The Russian regulatory approval does not confer equivalence with approvals from these agencies, each of which applies its own independent evidentiary standards. Outside Russia, Semax is typically obtained as a research chemical.
- What is BDNF and why is it relevant to Semax?
- Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival, growth, and differentiation of neurons and synapses. It plays a central role in synaptic plasticity — including the formation of new memories and learning consolidation — and declines with age and in certain neurological conditions. Semax has been reported to upregulate BDNF mRNA expression and trkB receptor levels in rodent hippocampus (Dolotov et al., 2006, Brain Research; PMID 16996037). This finding is the primary mechanistic basis for community interest in Semax as a nootropic; however, BDNF upregulation from Semax has not been measured or confirmed in controlled human trials.
- Why is it difficult to evaluate Semax's evidence?
- The majority of Semax clinical research was conducted in Russia and published in Russian-language journals that are not fully indexed in international databases such as PubMed. This means that while a clinical record exists in the Russian regulatory context, the evidence cannot be independently evaluated with the same ease as research published in major English-language peer-reviewed journals. The international research community has not conducted independent replication of the primary Russian clinical trials. This evidence limitation should be clearly understood before interpreting Semax as having a well-established clinical evidence base.
- Is intranasal the correct route for Semax?
- Intranasal administration is the route used in the Russian-approved pharmaceutical formulation, and it is the route for which most clinical data exists. The theoretical rationale is that intranasal delivery allows some degree of nose-to-brain transport via the olfactory pathway, which may be relevant for a centrally-acting neuropeptide. Community reports also describe injectable formulations. The bioavailability and CNS penetration of injectable Semax relative to intranasal administration have not been comparatively characterised in peer-reviewed international literature.
- Is Semax legal to buy or use outside Russia?
- Outside Russia, Semax is not approved for human therapeutic use in the United States, EU, Australia, Canada, or the UK. In most jurisdictions it is sold as a research chemical. Regulatory status varies by country and is subject to change; verify current status with a qualified legal or clinical professional. Within Russia, licensed pharmaceutical Semax is available through regulated pharmacy channels.